Fredun Pharmaceuticals Ltd share price headed higher 5.45% to Rs 1109.75 after the company's net profit surged by 21.80% to Rs 13.13 crore, while revenue from operations improved marginally 8.25% to Rs 227.76 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, easing 6.18%. It has inched up 0.41% over last one week and moving up by 11.45% in last one month while the market capitalization of Fredun Pharmaceuticals Ltd has sharply increased by 22.33% and 40.82% in the same period respectively. Profit before tax (PBT) of Fredun Pharmaceuticals Ltd stood at Rs 20.55 crore in Q2 FY26, surging by 127.32% year-on-year, and expanding by 82.67% quarter-on-quarter. EBITDA came in at Rs 33 crore, rallying 92.70% YoY and rising by 13.37% sequentially. Total expenses grew marginally by 6.28% to Rs 199.08 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 179.73 crore, inching up 2.47% YoY, while employee benefits expense was at Rs 7.12 crore, tanking by 19.64% YoY. For the TTM ended FY26, revenue from operations soared by 40.21% to Rs 633.33 crore, while net profit jumped 65.25% to Rs 32.62 crore, compared to previous TTM. EBITDA jumped by 5712% to Rs 94.54 crore, and PBT witnessed a strong rise of 70.97% to Rs 47.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 115.25 crore in FY26, as against Rs 29.06 crore in FY25. Fredun Pharmaceuticals Ltd rallied 227.89% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 3.20% during the same period.
